Current Treatment Landscape for AL Amyloidosis


Jeffrey Zonder, MD, offers an overview of the current treatment landscape for AL amyloidosis.

This is a video synopsis/summary of a Peer Exchange involving Heather Landau, MD; Vaishali Sanchorawala, MD; and Jeffrey Zonder, MD.

Panelists discuss the treatment landscape for light chain (AL) amyloidosis, focusing on targeting plasma cells to reduce toxic light chains. They note challenges in adapting multiple myeloma therapies for amyloidosis due to tolerability issues with certain agents. The primary FDA-approved induction regimen is cyclophosphamide-bortezomib-dexamethasone (CyBorD), which demonstrates effectiveness in reducing misfolded light chains, especially with the addition of the monoclonal antibody daratumumab.

Although the regimen significantly improves organ function, it does not impact early survival rates, particularly for patients at high risk of complications. The discussion highlights the ongoing complexities in treating AL amyloidosis, such as balancing effectiveness and survival outcomes.

Video synopsis is AI-generated and reviewed by OncLive® editorial staff.

Related Videos
Video 2 - "Targeting RET Fusion in Brain Tumor"
Video 8 - "Post-Thyroidectomy Management: Thyroid Hormone Replacement and TSH Suppression"
Video 7 - "The Importance of Thyroidectomy in DTC Patient Care"
Video 6 - "Patient Case 2: A 62-Year-Old Woman with Metastatic Rectal Cancer"
Video 5 - "Adverse Events Associated With TAS-102 Plus Bevacizumab in CRC"
Video 3 - "5-Year Data from the MonarchE Trial Investigating Abemaciclib in HR+, HER2- High-Risk, Early Breast Cancer"
Video 14 - "Patient Profile 2: Patient Progression After Frontline HCC Therapy"
Video 13 - "Combining Liver-directed and Systemic Therapies in HCC"
Video 6 - "Employing Liquid Biopsies and ctDNA in DTC Diagnostic Strategies"
Video 5 - "The Role of Molecular Diagnostics in Real-World DTC Management"
Related Content